Search

5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer

Publication: Bill

Preston, M. A., K. M. Wilson, S. C. Markt, R. Ge, C. Morash, M. J. Stampfer, M. Loda, E. Giovannucci, L. A. Mucci, and A. F. Olumi. 2014. 5α-Reductase Inhibitors and Risk of High-Grade or Lethal Prostate Cancer.

Activation of AKR1C1/ERβ induces apoptosis by downregulation of c-FLIP in prostate cancer cells: A prospective therapeutic opportunity

Publication: Bill

Yun, H., J. Xie, A. F. Olumi, R. Ghosh, and A. P. Kumar. 2015. Activation of AKR1C1/ERβ Induces Apoptosis by Downregulation of C-FLIP in Prostate Cancer Cells: A Prospective Therapeutic Opportunity.

Understanding temporal trends in medical costs associated with progression to metastatic prostate cancer

Publication: Bill

Frendl, D. M., and A. F. Olumi. 2017. Understanding Temporal Trends in Medical Costs Associated With Progression to Metastatic Prostate Cancer.

Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long-term Results of a Single-institution Experience

Publication: Bill

Rodin, D., M. Drumm, R. Clayman, D. L. Buscariollo, S. Galland-Girodet, A. Eidelman, A. S. Feldman, et al. 2017. Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long-Term Results of a Single-Institution Experience.

Metformin inhibits the proliferation of benign prostatic epithelial cells

Publication: Bill

Wang, Z., X. Xiao, R. Ge, J. Li, C. W. Johnson, C. Rassoulian, and A. F. Olumi. 2017. Metformin Inhibits the Proliferation of Benign Prostatic Epithelial Cells.

Would You Recommend Prostate-Specific Antigen Screening for This Patient?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center

Publication: Bill

Burns, R. B., A. F. Olumi, D. K. Owens, and G. W. Smetana. 2019. Would You Recommend Prostate-Specific Antigen Screening for This Patient?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.

Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy

Publication: Bill

Wang, Z., T. Deng, X. Long, X. Lin, S. Wu, H. Wang, R. Ge, et al. 2020. Methylation of SRD5A2 Promoter Predicts a Better Outcome for Castration-Resistant Prostate Cancer Patients Undergoing Androgen Deprivation Therapy.

Search

Search results

5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer

Activation of AKR1C1/ERβ induces apoptosis by downregulation of c-FLIP in prostate cancer cells: A prospective therapeutic opportunity

Understanding temporal trends in medical costs associated with progression to metastatic prostate cancer

Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long-term Results of a Single-institution Experience

Metformin inhibits the proliferation of benign prostatic epithelial cells

Would You Recommend Prostate-Specific Antigen Screening for This Patient?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center

Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy

Zonal Growth Pattern of the Prostate Is Affected by Age and Body Mass Index

Correction: Sirt1 coordinates with ERα to regulate autophagy and adiposity

Effect of TNF-α Inhibitor Therapy on Growth of the Prostate Gland